Scholarlink

Background <p>Terazosin (TZ) is widely prescribed for hypertension and benign prostatic hyperplasia. Recent studies suggest that TZ enhances glycolysis and may protect against neurodegenerative diseases.</p> Methods <p>We tested the hypothesis that TZ is neuroprotective in Alzheimer’s disease (AD) in a yeast model, a mouse model, and two human datasets.</p> Results <p>We report four main results. First, TZ increased ATP levels in a <i>Saccharomyces cerevisiae</i> mutant with impaired metabolism, and reduced Amyloid-beta42 (Aβ42) aggregation. Second, in 5xFAD mice, TZ attenuated amyloid pathology and rescued cognitive impairments in spatial memory and interval timing. Third, in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, AD patients taking glycolysis-enhancing drugs had a slower progression of both cognitive dysfunction and metabolic neuroimaging biomarkers (18&#xa0;F-fluorodeoxyglucose positron emission tomography (FDG-PET)). Finally, in the Merative Marketscan dataset, patients taking glycolysis-enhancing drugs had lower risks of developing AD.</p> Conclusion <p>These data provide preliminary evidence that glycolysis-enhancing drugs have therapeutic potential in AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Glycolysis-enhancing α1-adrenergic antagonists have therapeutic potential in Alzheimer’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月9日

查看全文
  • Qiang Zhang,
  • Jordan L Schultz,
  • Jacob E Simmering,
  • Braedon Q Kirkpatrick,
  • Matthew A Weber,
  • Sydney Skuodas,
  • Tara Hicks,
  • Grace Pierce,
  • Margaret Laughlin,
  • Benu George,
  • Aimee X Bertolli,
  • Travis Larson,
  • Ramasamy Thangavel,
  • Mayu Oya,
  • David K Meyerholz,
  • Georgina Aldridge,
  • Jan Fassler,
  • Nandakumar S. Narayanan

摘要

Background

Terazosin (TZ) is widely prescribed for hypertension and benign prostatic hyperplasia. Recent studies suggest that TZ enhances glycolysis and may protect against neurodegenerative diseases.

Methods

We tested the hypothesis that TZ is neuroprotective in Alzheimer’s disease (AD) in a yeast model, a mouse model, and two human datasets.

Results

We report four main results. First, TZ increased ATP levels in a Saccharomyces cerevisiae mutant with impaired metabolism, and reduced Amyloid-beta42 (Aβ42) aggregation. Second, in 5xFAD mice, TZ attenuated amyloid pathology and rescued cognitive impairments in spatial memory and interval timing. Third, in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, AD patients taking glycolysis-enhancing drugs had a slower progression of both cognitive dysfunction and metabolic neuroimaging biomarkers (18 F-fluorodeoxyglucose positron emission tomography (FDG-PET)). Finally, in the Merative Marketscan dataset, patients taking glycolysis-enhancing drugs had lower risks of developing AD.

Conclusion

These data provide preliminary evidence that glycolysis-enhancing drugs have therapeutic potential in AD.